

## **Supplementary Materials and Methods**

### **Immunohistochemistry and immunofluorescence**

Paraffin-embedded tissues were sectioned, deparaffinized, steamed in Target Retrieval Solution Ready to Use (Dako) for 40 minutes, blocked with Protein Block Serum-Free (Dako), and then incubated with primary antibodies overnight at 4°C. For IHC, primary antibodies were followed by secondary antibodies (Vector Laboratories) and then detected with 3,3'-Diaminobenzidine kit (Vector Laboratories). For IF, primary antibodies were followed by Alexa Fluor Dye secondary antibodies (Thermo Fisher Scientific) and mounted with Vectashield hard-set mounting medium with DAPI counterstain (Vector Laboratories). Images were captured at room temperature on a Nikon E800 fluorescence microscope with 40X Plan Apo objective and a Nikon DS-QiMc camera with Nikon Elements imaging software (vAR 3.0).

### **Immunoblotting**

Cells were lysed in RIPA buffer (Sigma) supplemented with protease and phosphatase inhibitors (Sigma), and protein concentration of lysates was quantified using a BCA kit (Thermo Fisher Scientific). Lysates were fractionated on NuPAGE gels (Invitrogen). Proteins were transferred to poly-vinylidene difluoride membranes (Millipore), blocked, and then incubated with primary antibodies. Blots were developed using enhanced chemiluminescence (Thermo Fisher Scientific).

### **RNA isolation and quantitative Real-Time PCR**

Total RNA was purified using RNeasy Plus Minikit (Qiagen). First-strand cDNA was synthesized using random hexamer primers (Promega) and Ready-To-Go You-Prime First-Strand Beads (GE Healthcare), according to the manufacturers' instructions. Quantitative PCR was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems) using TaqMan Fast Advanced PCR

Master Mix (Applied Biosystems) with TaqMan primers. StepOne software (v2.3, Applied Biosystems) was used to calculate threshold cycle values (Applied Biosystems).

### **Colony forming unit assay**

Adult prostate MSCs, expanded between passages 1 and 3, were plated at the following seeding densities per T25 flask:  $5 \times 10^4$ ,  $1.5 \times 10^5$ , and  $2.5 \times 10^5$  cells. Fetal MSCs, expanded between passages 2 and 7, were plated at the following seeding densities per T25 flask:  $5 \times 10^3$ ,  $1 \times 10^4$ , and  $2 \times 10^4$  cells. Three biological replicates were performed per experimental group and each seeding density was technically replicated two times. Cells were grown in DMEM supplemented with 10% FBS, GlutaMAX, and penicillin/streptomycin at 5% CO<sub>2</sub> and 37°C for 21 days. For exogenous ASPN, media contained either vehicle or 100ng/mL recombinant mouse ASPN (Origene). At 21 days, representative photographs were taken of each condition using a TE-200 inverted microscope (Nikon). Medium was aspirated from each flask, colonies were washed twice with PBS, and stained with 0.2% crystal violet in 50% methanol for 5 minutes. Flasks were destained by washing twice with distilled water. Flasks were air-dried and colonies counted.

### **Cell proliferation assay**

*Aspn*<sup>+/+</sup> and *Aspn*<sup>-/-</sup> fetal MSCs, expanded between passages 1 and 3, were plated at 2500 cells/well of a 48-well plate and cultured for 1-7 days in DMEM supplemented with 10% FBS, GlutaMAX (1X), penicillin (100 U/mL), and streptomycin (100 µg/mL) at 5% CO<sub>2</sub> and 37°C. At each time point, media was removed, cells were incubated with 0.5 mg/mL Thiazolyl Blue Tetrazolium Bromide (Sigma) in complete media for one hour at 37°C and 5% CO<sub>2</sub>. This solution was then removed, cells were incubated with DMSO and gently agitated for 5 minutes in the dark at room temperature, and the absorbance of the DMSO solution was read at 570 nm using an accuSkan FC Microplate Photometer (Thermo Fisher Scientific). Three biological replicates were

assessed per experimental group and each biological replicate had three technical replicates per time point.

### **Cell migration assays**

To assess migration, cells were cultured in 6-well plates and grown to 100% confluency. Then, using a 1000  $\mu$ L pipette tip, a scratch in the form of the letter “H” was made through the lawn of cells, the media was replaced, and a 0 time point picture was taken at spots with relatively equal scratch widths. At subsequent time points, pictures were taken at the same spots and percent closure of the scratch was calculated using the MRI Wound Healing Tool (ImageJ). Two biological replicates were performed per experimental group and each biological replicate was represented as the average of  $\geq 9$  technical replicates. For *Aspn*<sup>+/+</sup> and *Aspn*<sup>-/-</sup> fetal MSCs, which demonstrated a cell proliferation difference, we instead utilized a trans-well assay (Millipore) to assess cell migration. Fetal MSCs, expanded between passages 1 and 3, were serum-depleted for 24 hours, plated at  $1.5 \times 10^5$  cells per well in serum-depleted media and were allowed to migrate toward the serum-replete (10% FBS) lower chamber via 8  $\mu$ m pores. At four hours post-seeding, cell migration toward the lower chamber was assessed via cell stain-colorimetry according to the manufacturer’s protocol. Three independent samples were assessed per experimental group. For exogenous ASPN, fetal MSCs were serum and calcium depleted for 24 hours, plated in serum-depleted and calcium low (80 mg/mL) media with either vehicle, 100 ng/mL recombinant mouse ASPN (Origene), 1 mM BAPTA, or 1 mM BAPTA plus ASPN.

### **Cytoskeletal remodeling**

Cytoskeletal remodeling of cells was assessed as previously described (1). Briefly, serum-deprived cells adherent to collagen-coated plates were incubated for 20 minutes with  $\sim 5 \times 10^5$  ferrimagnetic RGD-coated microbeads. The synthetic RGD peptide binds avidly to cell surface integrin receptors and its subsequent movement couples that of the inner remodeling

cytoskeleton. Unbound beads were washed away and under microscopic observation, the spontaneous displacement of individual microbeads was recorded at set time intervals and graphed as mean square displacement ( $\text{nm}^2$ ) over time (seconds). Potential confounders, such as microscope stage drift, were corrected for in the analysis. Two independent clones were assessed per experimental group.

### **PELICAN study**

All studies using human tissue were approved by the Johns Hopkins Institutional Review Board. PELICAN (Project to ELIminate lethal CANcer) Rapid Autopsy Study of Prostate Cancer has been previously described (2). Patients were consented to participate in the Johns Hopkins Medicine IRB-approved study between 1995 and 2005. A study tissue microarray (TMA) was constructed from formalin fixed tissue taken at autopsy (n=16 patients).

At least three cores (0.6 mm) were sampled from each metastasis.

Four-micrometer-cut sections were stained for ASPN (Sigma Prestige) by IHC. Cases were scored by urologic pathologists for stromal ASPN expression. Using established scoring schemes (3), ASPN intensity was evaluated and assigned an incremental score of 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The extent of stromal staining was assigned a percentage from 0-100%. For each core, an ASPN score was calculated by multiplying the intensity score and the extent score (H-score). The mean H-score was recorded for each metastatic site. Fifteen of the 16 patients were evaluable, and the mean number of evaluable metastatic sites per patient was 4 (ranging from 2 to 6).

### **CP1 *E. coli* mouse model of prostate inflammation**

All animal procedures were performed under JHU approved Institutional Animal Care and Use Committee (IACUC) protocol. Mice were purchased from The Jackson Laboratory and maintained under standard pathogen free conditions. CP1 bacteria was originally isolated from the expressed

prostatic secretions of a patient with chronic prostatitis (4). CP1 is an *E. coli* strain of the B1 clonal group. The CP1 bacteria mouse model of prostate inflammation was induced as described previously (5). In brief, a single dose of  $1 \times 10^8$  CFU CP1 or saline control in 10  $\mu$ l of PBS was delivered to the urethra by catheterization of anaesthetized 8 week old male C57BL/6J mice.

### **MSC isolation**

*Human:* MSCs were isolated from human tissue in accordance with IRB-approved protocols as described previously (6). Briefly, fetal prostate samples (~14-18 weeks gestation) were obtained in accordance with federal and state guidelines, dissociated into single cell suspensions, and cultured as described previously (7). Prostate tissue from young men (<25 years old) was obtained through a rapid organ donor program organized by the National Disease Research Interchange (NDRI). Prostate cancer tissue was obtained from patients undergoing a radical prostatectomy at the Johns Hopkins Brady Urological Institute via the Prostate Biospecimen Repository. Bone marrow-derived MSCs were obtained from healthy bone marrow donors through the Johns Hopkins Biospecimen Repository Core or purchased from RoosterBio, Inc. Normal prostate fibroblasts were obtained as described previously (8). Tissues were dissociated and grown in RoosterNourish™-MSC (RoosterBio) to generate primary stromal cultures. RNA was isolated when cultures were at a confluence of approximately 80%.

*Mouse:* All animal protocols were approved by the Johns Hopkins University Animal Care and Use Committee. UGM and UGE were isolated from mice as described previously (9, 10). The UGS was removed from C57BL/6J embryonic day 15.5 males and then digested in 1% trypsin (Gibco Thermo Fisher Scientific) in Hank's Balanced Salt Solution (Gibco Thermo Fisher Scientific) at 4°C for 90 minutes. Following digestion, UGS were washed with DMEM (Gibco Thermo Fisher Scientific) containing 10% FCS (Gibco Thermo Fisher Scientific). UGM and UGE were then separated with a fine gauge needle. Fetal MSCs were isolated by euthanizing

C57BL/6J *Aspn*<sup>+/+</sup> or *Aspn*<sup>-/-</sup> pregnant females at embryonic day 13.5 via isoflurane inhalation followed by cervical dislocation. The uterine horns were dissected, and each embryo was separated from its placenta and embryonic sac. The head and red organs were removed and discarded, while the remaining tissue was minced with a sterile razor, and digested with trypsin + DNase I (1 mg/mL) for single cell isolation. Adult prostate MSCs were isolated by euthanasia of  $\geq 24$ -week-old male mice and *en bloc* removal of the genitourinary system (GU=prostate, seminal vesicles, bladder, vas deferens, urethra). The prostatic lobes were microdissected from the rest of the GU, finely minced with a sterile razor, digested in DMEM + 10% FBS + 1:10 dilution of collagenase/hyaluronidase for one hour at 37°C, triturated in pre-warmed 1X PBS + DNase I (1 mg/mL), filtered through a 40  $\mu$ m cell strainer, and plated on culture flasks. Fetal MSCs and adult prostate MSCs were cultured in DMEM supplemented with 10% FBS, GlutaMAX (1X), penicillin (100 U/mL), and streptomycin (100  $\mu$ g/mL). Adult bone marrow-derived MSCs were isolated as described previously (11, 12). In brief,  $\geq 24$ -week old male mice were euthanized and their hind legs removed. Femurs and tibias were isolated by removal of attached tendons and muscles, and bones were cracked using a sterile mortar and pestle into ice-cold 1X PBS supplemented with 2% FBS and EDTA (1 mM) to release the bone marrow. Bone marrow was plated on culture flasks and grown at 37°C in hypoxia (1% O<sub>2</sub>, 5% CO<sub>2</sub>) until fibroblast colonies were visible (~14 days), then hematopoietic cells were removed by CD45 and TER119 negative selection (EasySep Mouse Mesenchymal Stem/Progenitor Cell Enrichment Kit, STEMCELL Technologies). Bone marrow-derived murine MSCs were cultured in MesenCult Expansion Media (STEMCELL Technologies). Adult compact bone-derived MSCs were isolated as described previously (13). In brief,  $\geq 24$ -week old male mice were euthanized and their hind legs removed. Femurs and tibias were isolated by removal of attached tendons and muscles, and bones were cracked using a sterile mortar and pestle into ice-cold PBS supplemented with 2% FBS and EDTA (1 mM) to release the bone marrow. Remaining bone fragments were washed by gentle agitation an additional 3-4 times with ice cold PBS until all bone marrow was released (indicated by loss of

red coloration). Bone fragments were then digested at 37°C shaking for 1 hour in complete media containing 1 mg/mL collagenase II (Gibco). Following digestion, bone fragments were washed several times with complete media, seeded onto culture flasks, and grown at 37°C in hypoxia (1% O<sub>2</sub>, 5% CO<sub>2</sub>) until adherent cells were detected.

## **MSC lineage specific differentiation assays**

### *Osteogenic and adipogenic Differentiation*

Fetal MSCs, expanded between passages 1 and 3, were cultured under hypoxic conditions until reaching 80-90% confluency. Normal growth medium was then aspirated and replaced with either osteogenic or adipogenic differentiation-inducing medium (STEMCELL Technologies). Cells incubated at 37°C in hypoxia (1% O<sub>2</sub>, 5% CO<sub>2</sub>), and differentiation media was changed every 3-4 days until bone matrix formation or intracellular lipid droplets was observed (14-21 days). For BMP inhibition, osteogenic medium (STEMCELL Technologies) contained 250 nM LDN-193189 (SelleckChem) or vehicle control. For exogenous ASPN, osteogenic medium (STEMCELL Technologies) contained 100 ng/mL recombinant mouse ASPN (Origene) or vehicle control. Osteogenic and adipogenic differentiation was detected by Alizarin Red and Oil Red O staining, respectively. Alternatively, cells were harvested for RNA isolation and lineage-specific markers were detected by qRT-PCR. Two biological replicates and three technical replicates were performed per experimental group and condition.

Osteogenic-differentiated fetal MSCs were washed with PBS, fixed in ice cold 70% ethanol for one hour at room temperature, washed three times with distilled water, and stained with 2% Alizarin Red staining solution for one hour at room temperature. Cells were then washed twice with distilled water and mineralized nodules were present as bright red stained spots.

Adipogenic-differentiated fetal MSCs were washed with PBS, fixed in 10% formaldehyde for 30 minutes at room temperature, washed three times with distilled water, rinsed once with

60% isopropanol, and stained with 0.5% Oil Red O in isopropanol for 15 minutes at room temperature. Cells were then washed three times with distilled water and lipid droplets were present as bright red intracellular vesicles.

### Chondrogenic differentiation

The method of chondrogenic differentiation was adapted from a prior report (14). Fetal MSCs ( $5 \times 10^5$  total cells) expanded between passages 1 and 3, were pelleted in a 14 mL polypropylene tube and incubated with chondrogenic differentiation-inducing media (STEMCELL Technologies). Cells incubated at 37°C in normoxia with the cap loosened to allow adequate airflow, and differentiation media was changed every 3-4 days for 21 days. Cartilage pellets were then harvested for paraffin-embedding and Alcian Blue staining or RNA isolation for detection of lineage-specific markers by qRT-PCR. Two biological replicates were performed per experimental group. For RNA isolation, more than 10 technical replicate pellets were pooled.

Chondrogenic pellets were fixed in 10% formalin for 30 minutes at room temperature, paraffin-embedded, cut into 6µm sections, deparaffinized, hydrated in distilled water, and stained with Alcian Blue staining solution for 30 minutes at room temperature. The slide was then washed in distilled water, dehydrated, cleared, and mounted. The cartilaginous matrix was present as a blue stain surrounding the cells.

### **Gene expression analysis**

Gene expression was performed on WPMY-1-ASPEN Neo, WPMY-1-ASPEN D14, and WPMY-1-ASPEN D13 clones using Affymetrix Human Clariom D arrays. Differential gene expression of *Aspn*<sup>+/+</sup> and *Aspn*<sup>-/-</sup> fetal MSCs and WPMY-1-ASPEN Neo, WPMY-1-ASPEN D14, and WPMY-1-ASPEN D13 clones was analyzed using Transcriptome Analysis Console (Applied Biosystems).



## References

1. An SS, Fabry B, Mellema M, Bursac P, Gerthoffer WT, Kayyali US, et al. Role of heat shock protein 27 in cytoskeletal remodeling of the airway smooth muscle cell. *J Appl Physiol* (1985). 2004;96:1701-13.
2. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. *Nature*. 2015;520:353-7.
3. Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, et al. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer. *Clin Cancer Res*. 2015.
4. Rudick CN, Berry RE, Johnson JR, Johnston B, Klumpp DJ, Schaeffer AJ, et al. Uropathogenic *Escherichia coli* induces chronic pelvic pain. *Infect Immun*. 2011;79:628-35.
5. Simons BW, Durham NM, Bruno TC, Grosso JF, Schaeffer AJ, Ross AE, et al. A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. *J Pathol*. 2015;235:478-89.
6. Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, et al. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. *Oncotarget*. 2017.
7. Guo C, Liu H, Zhang BH, Cadaneanu RM, Mayle AM, Garraway IP. Epcam, CD44, and CD49f distinguish sphere-forming human prostate basal cells from a subpopulation with predominant tubule initiation capability. *PLoS One*. 2012;7:e34219.
8. Gao J, Arnold JT, Isaacs JT. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. *Cancer Res*. 2001;61:5038-44.
9. Hurley PJ, Hughes RM, Simons BW, Huang J, Miller RM, Shinder B, et al. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. *Cancer Res*. 2015;75:4322-34.

10. Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. *Proc Natl Acad Sci U S A*. 109:14977-82.
11. Phinney DG. Isolation of mesenchymal stem cells from murine bone marrow by immunodepletion. *Methods Mol Biol*. 2008;449:171-86.
12. Boregowda SV, Krishnappa V, Chambers JW, Lograsso PV, Lai WT, Ortiz LA, et al. Atmospheric oxygen inhibits growth and differentiation of marrow-derived mouse mesenchymal stem cells via a p53-dependent mechanism: implications for long-term culture expansion. *Stem cells*. 2012;30:975-87.
13. Zhu H, Guo ZK, Jiang XX, Li H, Wang XY, Yao HY, et al. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. *Nat Protoc*. 2010;5:550-60.
14. Solchaga LA, Penick KJ, Welter JF. Chondrogenic differentiation of bone marrow-derived mesenchymal stem cells: tips and tricks. *Methods Mol Biol*. 2011;698:253-78.

## Key Resources

### REAGENT or RESOURCE

#### Antibodies

Rabbit Anti-ASPEN antibody  
Mouse Anti-Vimentin antibody  
Rabbit anti-phospho SMAD1/5/9 antibody  
Rabbit anti-SMAD1 antibody  
Mouse anti-GAPDH antibody  
Mouse anti-CK8 antibody  
Rabbit anti-CK14 antibody  
Rabbit anti-Ki67 antibody  
Mouse anti-FLAG  
Rabbit anti-BMP4  
Mouse anti-SMA  
APC/Cy7 Rat anti-mouse CD45 antibody  
APC Rat anti-mouse CD105 antibody  
PE/Cy7 Armenian Hamster anti-mouse/rat CD29 antibody  
FITC Rat anti-mouse Ly-6A/E (Sca-1) antibody  
Ly6G  
Ly6C  
CD11b  
CD11c  
CCR2  
F4/80  
CD3  
CD4  
CD8a  
FoxP3  
CD44  
ImmPRESS HRP anti-mouse IgG antibody, made in Horse  
ImmPRESS HRP anti-rabbit IgG antibody, made in Horse  
F(ab)2-Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488  
Donkey anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 594  
IgG agarose  
anti-FLAG M2 magnetic beads  
3x FLAG peptide

#### Bacterial and Virus Strains

CP1 *E. coli* strain

#### Biological Samples

Human Primary Prostate Cancer  
Metastatic Prostate Cancer TMA  
Matched prostate inflammation & cancer tissue

#### Chemicals, Peptides, and Recombinant Proteins

RGD-coated microbeads  
FuGENE HD Transfection Reagent  
LIVE/DEAD Fixable Aqua Dead Cell Stain kit (405nm excitation)  
MesenCult Osteogenic Stimulatory Kit (Mouse)  
MesenCult Adipogenic Stimulatory Supplement (Mouse)  
MesenCult ACF Chondrogenic Differentiation Medium  
Alizarin Red Staining solution  
Oil Red O solution  
Alcian-Blue Staining solution  
Recombinant Human BMP4  
Recombinant Mouse BMP4  
Recombinant Mouse ASPN generated in 293T cells  
Matrigel, Growth Factor Reduced (GFR)  
Recombinant Mouse EGF  
Y-27632 (ROCK inhibitor)  
5 $\alpha$ -Androstan-17 $\beta$ -ol-3-one (DHT)  
A83-01 (TGF $\beta$  inhibitor)  
Advanced DMEM/F12  
50X B-27 Supplement  
GlutaMAX  
HEPES  
Penicillin/Streptomycin (10,000 U/mL)  
10X Collagenase/Hyaluronidase  
Dispase (5 U/mL)  
10X DNase I  
Thiazolyl Blue Tetrazolium Bromide  
Target Retrieval Solution, Ready to Use  
Protein Block Serum-Free  
Antibody Diluent Reagent Solution, Ready-to-use  
ImmPACT DAB (3,3'-Diaminobenzidine) Peroxidase Substrate  
VECTASHIELD HardSet Antifade Mounting Medium with DAPI counterstain  
FcR Blocking Reagent, mouse  
TaqMan Fast Advanced Master Mix  
SimplyBlue SafeStain

#### Critical Commercial Assays

Pierce BCA Protein Assay Kit, Reducing Agent Compatible  
SuperSignal West Pico PLUS Chemiluminescent Substrate  
QCM 24-well Colorimetric Cell Migration Assay

### SOURCE

Sigma Prestige  
Sigma  
Cell Signaling Technology  
Cell Signaling Technology  
Santa Cruz Biotechnology  
Covance Research Products Inc  
Covance Research Products Inc  
Abcam  
Sigma  
R&D  
Dako  
BioLegend  
BioLegend  
BioLegend  
BioLegend  
BioLegend  
BioLegend  
BioLegend  
BioLegend  
BioLegend  
BD Pharmingen  
BioLegend  
BioLegend  
BioLegend  
BioLegend  
Vector Laboratories  
Vector Laboratories  
Thermo Fisher Scientific  
Thermo Fisher Scientific  
Sigma  
Sigma  
Sigma

Brian W. Simons (Simons et al., 2015)

Mayo Clinic Progression cohort (Hurley et al., 2016)  
PELICAN rapid autopsy study of prostate cancer  
Johns Hopkins School of Medicine

Steven S. An (An et al., 2004)

Promega  
Thermo Fisher Scientific  
STEMCELL Technologies  
STEMCELL Technologies  
STEMCELL Technologies  
Millipore  
Sigma  
Millipore  
Peprotech  
R & D  
Origene  
Corning  
BioLegend  
STEMCELL Technologies  
Sigma  
Tocris  
Thermo Fisher Scientific  
Life Technologies  
Life Technologies  
Life Technologies  
Life Technologies  
STEMCELL Technologies  
STEMCELL Technologies  
STEMCELL Technologies  
Sigma  
Dako  
Dako  
Invitrogen  
Vector Laboratories  
Vector Laboratories  
Miltenyi  
Thermo Fisher Scientific  
Invitrogen

Thermo Fisher Scientific  
Thermo Fisher Scientific  
Millipore

### IDENTIFIER

Cat# HPA008435 RRID:AB\_1845112  
Cat# V2258 RRID:AB\_261856  
Cat# 13820 RRID:AB\_2493181  
Cat# 9743 RRID:AB\_2107780  
Cat# sc-32233 RRID:AB\_627679  
Cat# MMS-162P-250 RRID:AB\_291334  
Cat# PRB-155P RRID:AB\_292096  
Cat# ab15580 RRID:AB\_443209  
Cat# F1804  
Cat# MAB5020  
Cat# M085129  
Cat# 103115 RRID:AB\_312980  
Cat# 120413 RRID:AB\_2277915  
Cat# 102221 RRID:AB\_528789  
Cat# 108105 RRID:AB\_313342  
Clone 1A8  
Clone HK1.4  
Clone M1/70  
Clone N418  
Clone SA203G11  
Clone BM8  
Clone 145-2C11  
Clone GK1.5  
Clone 53-6.7  
Clone 150D  
Clone IM7  
Cat# MP-7402 RRID:AB\_2336528  
Cat# MP-7401 RRID:AB\_2336529  
Cat# A-11017 RRID:AB\_2534084  
Cat# A-21207 RRID:AB\_141637  
Cat# A0919  
Cat# M8823  
Cat# F4799

Cat# E2311  
Cat# L34957  
Cat# 05504  
Cat# 05503  
Cat# 05455  
Cat# TMS-008-C  
Cat# O1391  
Cat# TMS-010-C  
Cat# 120-05  
Cat#5020-BP  
Custom  
Cat# 356230  
Cat# 713108  
Cat# 72302  
Cat# A8380  
Cat# 2939  
Cat# 12634-010  
Cat# 17504-044  
Cat# 35050-079  
Cat# 15630-080  
Cat# 15140-122  
Cat# 07912  
Cat# 07913  
Cat# 07900  
Cat# M2128  
Cat# S1700  
Cat# X0909  
Cat# 003218  
Cat# SK-4105  
Cat# H-1500  
Cat# 130-092-575  
Cat# 4444557  
Cat# LC6060

Cat# 23250  
Cat# 34580  
Cat# ECM508

